Clinical Trials · NCT03179995

Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy

TerminatedPhase 2Octreotide (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
Fox Chase Cancer Center
Enrollment
23
Start date
Jul 2017
Locations
2 sites, United States
Primary endpoint
Rates of Liver Recovery Will be Determined by Area Under the Curve (AUC) for Total Bilirubin and INR for Each Group
View Octreotide compound reference